D
Darrin P. Smith
Researcher at Institute of Cancer Research
Publications - 6
Citations - 910
Darrin P. Smith is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Gene targeting & HSPA2. The author has an hindex of 6, co-authored 6 publications receiving 882 citations. Previous affiliations of Darrin P. Smith include The Breast Cancer Research Foundation & Walter and Eliza Hall Institute of Medical Research.
Papers
More filters
Journal ArticleDOI
Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction
Kei Sakamoto,Afshan McCarthy,Darrin P. Smith,Kevin A. Green,D. Grahame Hardie,Alan Ashworth,Dario R. Alessi +6 more
TL;DR: These studies establish the importance of LKB1 in regulating AMPK activity and cellular energy levels in response to contraction and phenformin and reduce phosphorylation and activation of AMPKα2.
Journal ArticleDOI
Regulation of the Wnt signalling component PAR1A by the Peutz-Jeghers syndrome kinase LKB1.
James Spicer,Sydonia Rayter,Neville Young,Richard Elliott,Alan Ashworth,Darrin P. Smith,Darrin P. Smith +6 more
TL;DR: It is shown that L KB1 can modify transcription driven by the Wnt-regulated TCF response element, implicating LKB1 in a pathway known to play a key role in human colorectal tumorigenesis.
Journal ArticleDOI
LIP1, a cytoplasmic protein functionally linked to the Peutz-Jeghers syndrome kinase LKB1
TL;DR: Ectopic expression of both LKB1 and LIP1 in Xenopus embryos induces a secondary body axis, providing further evidence for a functional link between the two proteins and suggesting an unsuspected mechanistic link between these two syndromes.
Journal ArticleDOI
The mouse Peutz-Jeghers syndrome gene Lkb1 encodes a nuclear protein kinase.
TL;DR: It is shown that Lkb1 is most likely a nuclear protein and a nuclear localization signal within the protein sequence is defined, indicating that the defect in Peutz-Jeghers syndrome may directly result in changes in gene expression in the nucleus of target cells.
Journal ArticleDOI
Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
Alicia Okines,D. Gonzalez de Castro,David Cunningham,Ian Chau,Ruth E Langley,L.C. Thompson,Sally P. Stenning,C. Saffery,Yolanda Barbachano,Fareeda Y. Coxon,Gary Middleton,David R. Ferry,Tom Crosby,Srinivasan Madhusudan,Jonathan Wadsley,Justin Waters,Marcia Hall,Daniel Swinson,A. Robinson,Darrin P. Smith,Jorge S. Reis-Filho,Tom Samuel Waddell,L. Puckey,S. Hulkki Wilson,Zakaria Eltahir,M. Band,A C Wotherspoon +26 more
TL;DR: The RR of 52% in REAL3 with mEOC+P met pre-defined criteria to continue accrual to phase III and the frequency of the mutations was too low to exclude any prognostic or predictive effect.